#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	6620	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2542	616.3	0	.	n	.	0	C1450T	SNP	1450	1450	C	1926	1926	T	759	T,G,C	670,2,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	6620	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2542	616.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1660	1660	C	787	C,A,G,T	704,2,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	11268	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4098	656.5	0	.	n	.	0	A9G	SNP	9	9	A	621	621	G	776	G,A	720,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	11268	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4098	656.5	0	.	n	.	0	T695C	SNP	695	695	T	1307	1307	C	819	C,A,T	729,5,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	11268	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4098	656.5	0	.	n	.	0	T1971C	SNP	1971	1971	T	2583	2583	C	764	C,T,G	682,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	11268	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4098	656.5	1	SNP	n	A2045G	0	.	.	2045	2045	A	2657	2657	A	778	A	696	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	11268	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4098	656.5	1	SNP	n	C2597T	0	.	.	2597	2597	C	3209	3209	C	833	C,A,T,G	738,1,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_L_00516	folP.WHO_L_00516	1	1	539	662	folP	855	855	99.88	folP.l6.c4.ctg.1	2105	76.1	1	SNP	p	R229S	1	R229S	NONSYN	685	687	CGC	1327	1329	AGC	97;97;98	A;G;C	87;88;87	folP.WHO_L_00516:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	1278	gyrA	2751	2751	99.78	gyrA.l15.c4.ctg.1	3878	79.4	0	.	p	.	0	T243I	NONSYN	727	729	ACA	1321	1323	ATA	91;92;89	A;T,A;A,G,C	87;87,1;84,1,1	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	1278	gyrA	2751	2751	99.78	gyrA.l15.c4.ctg.1	3878	79.4	0	.	p	.	0	M250I	NONSYN	748	750	ATG	1342	1344	ATA	92;91;91	A;T;A,C	87;87;87,2	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	1278	gyrA	2751	2751	99.78	gyrA.l15.c4.ctg.1	3878	79.4	1	SNP	p	S91F	0	.	.	271	273	TCC	865	867	TCC	88;89;89	T;C;C	75;76;79	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	1278	gyrA	2751	2751	99.78	gyrA.l15.c4.ctg.1	3878	79.4	1	SNP	p	D95N	0	.	.	283	285	GAC	877	879	GAC	96;96;96	G;A;C	83;83;82	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	1278	gyrA	2751	2751	99.78	gyrA.l15.c4.ctg.1	3878	79.4	1	SNP	p	D95G	0	.	.	283	285	GAC	877	879	GAC	96;96;96	G;A;C	83;83;82	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_F_01564	mtrR.WHO_F_01564	1	1	539	552	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1835	72.9	0	.	p	.	0	T169P	NONSYN	505	507	ACG	1158	1160	CCG	113;113;113	C;C,G;G,T	98;102,1;96,2	.	.
mtrR.WHO_F_01564	mtrR.WHO_F_01564	1	1	539	552	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1835	72.9	1	SNP	p	G45D	0	.	.	133	135	GGC	786	788	GGC	128;128;128	G,A;G,C;C	113,1;110,1;114	mtrR.WHO_F_01564:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	340	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1707	48.5	0	.	n	.	0	.206T	INS	206	206	T	1054	1054	T	118	T	107	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1206	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3434	83.5	0	.	p	.	0	V421A	NONSYN	1261	1263	GTC	1817	1819	GCC	120;120;116	G,C;C,T;C	104,1;104,1;95	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1206	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3434	83.5	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1859	1861	GCA	105;107;104	G;C;A,G	89;95;86,1	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1206	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3434	83.5	1	SNP	p	D86N	0	.	.	256	258	GAC	812	814	GAC	74;73;72	G;A;C	61;54;60	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1206	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3434	83.5	1	SNP	p	S87I	0	.	.	259	261	AGT	815	817	AGT	73;74;75	A,C;G;T,G	57,1;64;62,1	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1206	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3434	83.5	1	SNP	p	S87W	0	.	.	259	261	AGT	815	817	AGT	73;74;75	A,C;G;T,G	57,1;64;62,1	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1206	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3434	83.5	1	SNP	p	S87R	0	.	.	259	261	AGT	815	817	AGT	73;74;75	A,C;G;T,G	57,1;64;62,1	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1206	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3434	83.5	1	SNP	p	S88P	0	.	.	262	264	TCC	818	820	TCC	76;76;75	T;C;C	62;64;63	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_W_01411c	parE.WHO_W_01411c	1	1	27	1202	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3271	88.4	1	SNP	p	G410V	0	.	.	1228	1230	GGT	1901	1903	GGT	101;102;102	G;G,T;T,G	87;83,1;74,2	parE.WHO_W_01411c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.22.001	penA.22.001	1	1	27	1228	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2550	111.7	1	SNP	p	A311V	0	.	.	931	933	GCA	1514	1516	GCA	153;159;160	G,T,C;C,A;A,C	131,2,1;137,1;136,1	penA.22.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1228	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2550	111.7	1	SNP	p	I312M	0	.	.	934	936	ATC	1517	1519	ATC	163;163;163	A;T,G;C	141;145,2;147	penA.22.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1228	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2550	111.7	1	SNP	p	V316P	0	.	.	946	948	GTG	1529	1531	GTG	166;165;165	G,C;T,G;G	148,1;147,1;147	penA.22.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1228	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2550	111.7	1	SNP	p	V316T	0	.	.	946	948	GTG	1529	1531	GTG	166;165;165	G,C;T,G;G	148,1;147,1;147	penA.22.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1228	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2550	111.7	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2033	2035	ACC	103;102;101	A;C;C,A	79;79;88,1	penA.22.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1228	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2550	111.7	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2087	2089	GCG	84;87;87	G;C;G	75;65;72	penA.22.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1228	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2550	111.7	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2087	2089	GCG	84;87;87	G;C;G	75;65;72	penA.22.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1228	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2550	111.7	1	SNP	p	G543S	0	.	.	1627	1629	GGT	2210	2212	GGT	102;104;102	G;G,T;T	96;94,1;94	penA.22.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1228	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2550	111.7	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2219	2221	GGC	97;98;98	G,T;G;C	85,1;87;87	penA.22.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1228	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2550	111.7	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2237	2239	CCG	102;101;101	C,A,T;C;G	88,1,1;91;89	penA.22.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	2148	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3591	140.3	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1885	1887	CTG	178;176;179	C,G,A,T;T,C,G,A;G,T,C,A	147,3,3,1;155,4,2,1;160,4,1,1	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	674	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2320	70.0	0	.	p	.	0	S22G	NONSYN	64	66	AGC	610	612	GGC	61;61;61	G;G;C	54;49;54	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	674	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2320	70.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	792	792	C	60	C	55	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	798	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	2368	81.2	0	.	p	.	0	T18M	NONSYN	52	54	ACG	714	716	ATG	110;110;112	A;T,C;G,T	97;95,1;100,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	798	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	2368	81.2	0	.	p	.	0	E41K	NONSYN	121	123	GAA	783	785	AAA	106;106;106	A;A;A	98;98;96	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	798	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	2368	81.2	0	.	p	.	0	E48G	NONSYN	142	144	GAA	804	806	GGA	103;102;102	G;G;A	92;92;93	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	798	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	2368	81.2	0	.	p	.	0	V75I	NONSYN	223	225	GTT	885	887	ATT	104;104;103	A,C;T;T	95,1;96;96	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	798	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	2368	81.2	0	.	p	.	0	T89S	NONSYN	265	267	ACC	927	929	AGC	98;98;97	A,G;G,T;C	88,1;90,1;88	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	798	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	2368	81.2	0	.	p	.	0	V98I	NONSYN	292	294	GTC	954	956	ATC	97;97;97	A;T;C	87;88;89	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	798	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	2368	81.2	0	.	p	.	0	.	MULTIPLE	358	359	AA	1019	1020	CG	99;99	C,A;G	92,2;88	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	798	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	2368	81.2	0	.	p	.	0	.	MULTIPLE	361	362	GA	1022	1024	CAG	101;101;101	C,G;A,C;G,A	92,1;90,1;92,2	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	798	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	2368	81.2	0	.	p	.	0	N122K	NONSYN	364	366	AAC	1026	1028	AAA	102;102;103	A;A,G;A	96;97,1;99	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	798	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	2368	81.2	0	.	p	.	0	F131Y	NONSYN	391	393	TTT	1053	1055	TAT	112;117;116	T,G;A;T,A	105,2;112;97,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	798	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	2368	81.2	0	.	p	.	0	N134E	NONSYN	400	402	AAT	1062	1064	GAG	114;115;114	G,T,C;A,C;G,A	100,1,1;103,1;100,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	798	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	2368	81.2	0	.	p	.	0	V135F	NONSYN	403	405	GTG	1065	1067	TTT	115;115;115	T,A;T,C;T,C	94,1;108,1;108,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	798	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	2368	81.2	0	.	p	.	0	G140K	NONSYN	418	420	GGA	1080	1082	AAA	116;116;117	A,C;A;A	109,1;110;111	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	798	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	2368	81.2	0	.	p	.	0	K143E	NONSYN	427	429	AAA	1089	1091	GAA	116;116;116	G,C,T;A;A	104,1,1;99;105	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	798	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	2368	81.2	0	.	p	.	0	V151A	NONSYN	451	453	GTA	1113	1115	GCA	114;112;112	G;C;A	107;103;104	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	798	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	2368	81.2	0	.	p	.	0	T213S	NONSYN	637	639	ACA	1299	1301	TCA	144;143;144	T,G;C;A	129,1;129;129	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	798	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	2368	81.2	0	.	p	.	0	G253Q	NONSYN	757	759	GGA	1419	1421	CAA	138;138;137	C,A;A,T;A	125,1;126,1;126	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	798	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	2368	81.2	0	.	p	.	0	.	INDELS	760	762	ACA	1423	1427	ATCAA	139;137;137;136;136	A;T,A,G;C,G;A,G;A,G	127;123,1,1;124,1;123,1;123,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	798	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	2368	81.2	0	.	p	.	0	.	INDELS	763	764	TG	1430	1432	AGT	135;135;133	A;G,A;T,G,C,A	118;120,1;110,2,1,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	798	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	2368	81.2	0	.	p	.	0	A257D	NONSYN	769	771	GCT	1437	1439	GAT	129;130;130	G;A;T	117;118;119	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	798	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	2368	81.2	0	.	p	.	0	T269S	NONSYN	805	807	ACC	1473	1475	AGC	135;134;134	A;G;C	120;118;121	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	798	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	2368	81.2	0	.	p	.	0	D293S	NONSYN	877	879	GAT	1545	1547	AGT	133;137;123	A,T;G;T,C	120,1;124;112,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	798	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	2368	81.2	0	.	p	.	0	N295D	NONSYN	883	885	AAC	1551	1553	GAC	125;121;123	G;A;C	114;111;111	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	798	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	2368	81.2	0	.	p	.	0	H296Y	NONSYN	886	888	CAC	1554	1556	TAC	123;124;127	T,G;A,T,G;C	111,1;112,1,1;117	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	798	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	2368	81.2	1	SNP	p	G120K	1	.	.	358	360	AAG	1019	1021	CGG	99;99;101	C,A;G;G	92,2;88;91	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	798	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	2368	81.2	1	SNP	p	D121N	0	.	.	361	363	GAC	1022	1025	CGC	101;101;102	C,G;G,A;C	92,1;92,2;97	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	798	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	2368	81.2	1	SNP	p	A121D	1	.	.	361	363	GAC	1022	1025	CGC	101;101;102	C,G;G,A;C	92,1;92,2;97	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	3502	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5488	153.3	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2269	2271	CAT	167;167;167	C,A;A,T;T,A	150,2;153,1;152,1	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	478	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1632	71.0	1	SNP	p	V57M	1	.	.	169	171	ATG	854	856	ATG	146;146;148	A;T;G	135;135;137	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
